Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacripep for Corneal Wound Healing After PRK
NCT06854393Phase 2Recruiting
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of Lacripep, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoint: Epithelial thickness assessment at 6 months. Started May 2025; status: recruiting.
02
Drugs
Lacripep
Beyond the preview
Go deeper on NCT06854393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854393.